ACT Therapeutics

ACT Therapeutics is a private biotech company developing next-generation CAR-T cell therapies for solid tumors. Publicly available information indicates the company was established in 2020 in South Korea and has described its core technology as the "ACT platform," an immune cell-based cell and gene therapy platform that uses viral vectors to engineer cells against cancer antigens. The company has emphasized overcoming the immunosuppressive tumor microenvironment in solid cancers, with animal efficacy and safety data disclosed in partnership materials. ACT Therapeutics has also announced a strategic collaboration with GenScript ProBio to support plasmid and viral vector development and GMP manufacturing for its first pipeline program and future candidates. Overall, the company appears to be an early-stage oncology cell therapy developer centered on a platform approach for solid tumor CAR-T innovation.